Ocugen, Inc/OCGN

$0.96

1.49%
-
1D1W1MYTD1YMAX

About Ocugen, Inc

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. The Company's technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. It is developing COVAXIN, which is a whole-virion inactivated intramuscular COVID-19 vaccine candidate for the North American market. It is also developing a inhaled mucosal vaccine platform, which includes OCU500, a bivalent COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 vaccine. Its modifier gene therapy platform is focused on addressing various retinal diseases, including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and Stargardt disease, with a single mutation-agnostic therapy.

Ticker

OCGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Shankar Musunuri

Employees

84

Headquarters

Malvern, United States
Website
ocugen.com

Ocugen, Inc Metrics

BasicAdvanced
$240.09M
Market cap
-
P/E ratio
-$0.32
EPS
3.45
Beta
-
Dividend rate

What the Analysts think about Ocugen, Inc

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
559.38% upside
High $8.00
Low $4.00
$0.96
Current price
$6.33
Average price target

Ocugen, Inc Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-14.1M
-38.43%
Profit margin
0%
-

Ocugen, Inc Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 14.29%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.10
-$0.07
-$0.10
-$0.06
-
Expected
-$0.10
-$0.11
-$0.07
-$0.07
-$0.07
Surprise
2.04%
-35.19%
36.36%
-14.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Ocugen, Inc stock

Buy or sell Ocugen, Inc stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing